Literature DB >> 7767952

Antibiotic C3368-A, a fungus-derived nucleoside transport inhibitor, potentiates the activity of antitumor drugs.

J Su1, Y C Zhen, C Q Qi, J L Hu.   

Abstract

Antibiotic C3368-A (CA) is produced by a fungus strain from a soil sample collected in Antarctica. CA markedly inhibited radiolabeled thymidine and uridine transport in mouse Ehrlich carcinoma cells, its 50% inhibitory concentration (IC50) being 4.6 and 7.7 microM, respectively. In clonogenic assay, CA displayed a synergistic effect with methotrexate (MTX), mitomycin C (MMC), 5-fluorouracil (5FU), and Adriamycin (ADR) against human oral epidermoid carcinoma KB cells. CA also markedly enhanced the inhibitory effect of 5FU and ADR on the proliferation of human hepatoma BEL-7402 cells as determined by the p-nitrophenyl-N-acetyl-beta-D-glucosaminide (NAG) enzyme-reaction assay. 5FU or ADR cytotoxicity was not augmented by CA in human fetal lung 2BS cells. In vivo, CA significantly potentiated the inhibitory effect of MMC against colon carcinoma 26 in mice. No significant augmentation of toxicity by the combination was found in treated mice. The results suggest that CA, the newly found nucleoside-transport inhibitor, may be useful in potentiation of the effect of antitumor drugs.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7767952     DOI: 10.1007/BF00689200

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  29 in total

1.  Potentiation of adriamycin cytotoxicity by dipyridamole against HeLa cells in vitro and sarcoma 180 cells in vivo.

Authors:  H Kusumoto; Y Maehara; H Anai; T Kusumoto; K Sugimachi
Journal:  Cancer Res       Date:  1988-03-01       Impact factor: 12.701

Review 2.  Biochemical strategy of cancer cells and the design of chemotherapy: G. H. A. Clowes Memorial Lecture.

Authors:  G Weber
Journal:  Cancer Res       Date:  1983-08       Impact factor: 12.701

3.  Potentiation of antimetabolite antitumor activity in vivo by dipyridamole and amphotericin B.

Authors:  S S Cao; Y S Zhen
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

4.  Salvage pathways as targets of chemotherapy.

Authors:  G Weber; H N Jayaram; K Pillwein; Y Natsumeda; M A Reardon; Y S Zhen
Journal:  Adv Enzyme Regul       Date:  1987

Review 5.  Advances in rational combination chemotherapy.

Authors:  L E Damon; E C Cadman
Journal:  Cancer Invest       Date:  1986       Impact factor: 2.176

6.  Augmentation of methotrexate cytotoxicity in human colon cancer cells achieved through inhibition of thymidine salvage by dipyridamole.

Authors:  T J Van Mouwerik; C A Pangallo; J K Willson; P H Fischer
Journal:  Biochem Pharmacol       Date:  1987-03-15       Impact factor: 5.858

7.  Sequence-dependent synergism between dichloromethotrexate and cisplatin in a human colon carcinoma cell line.

Authors:  A F Sobrero; J R Bertino
Journal:  Cancer Treat Rep       Date:  1985-03

8.  Modulation of vinblastine sensitivity by dipyridamole in multidrug resistant fibrosarcoma cells lacking mdr1 expression.

Authors:  D R Shalinsky; M L Slovak; S B Howell
Journal:  Br J Cancer       Date:  1991-10       Impact factor: 7.640

9.  Synergistic inhibitory effects of dipyridamole and vincristine on the growth of human leukaemia and lymphoma cell lines.

Authors:  M Hirose; E Takeda; T Ninomiya; Y Kuroda; M Miyao
Journal:  Br J Cancer       Date:  1987-10       Impact factor: 7.640

10.  Potentiation of methotrexate lymphocytotoxicity in vitro by inhibitors of nucleoside transport.

Authors:  J M Hughes; M H Tattersall
Journal:  Br J Cancer       Date:  1989-03       Impact factor: 7.640

View more
  1 in total

1.  Possibility of contribution of nucleoside transport systems to pirarubicin uptake by HL60 cells but not mononuclear cells.

Authors:  K Nagasawa; N Ohnishi; T Yokoyama
Journal:  Jpn J Cancer Res       Date:  1998-06
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.